Phase 1B General Practice Vaccine Rollout- DoH Update 2 April 2021

Following reports of a specific clotting event following a COVID-19 Vaccination the DoH have released a number of statements

Joint statement from acting Australian Government Chief Medical Officer, Professor Michael  Kidd and Head of the Therapeutic Goods Administration Adj. Professor John Skerritt:

https://health.gov.au/news/joint-statement-on-astrazeneca-covid-19-vaccine

Updated ATAGI statement for healthcare providers:

https://health.gov.au/news/atagi-statement-healthcare-providers-specific-clotting-condition-reported-after-covid-19-vaccination

ATAGI statement for consumers:

https://health.gov.au/news/atagi-statement-consumers-specific-clotting-condition-after-covid-19-vaccination

TGA statement:

https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination

Additional ATAGI statement:

https://health.gov.au/news/atagi-statement-covid-19-vaccination-reported-case-of-thrombosis

Please Login to post a comment